ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nosocomial Pneumonia (NP)
Conditions
Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)
Trial Timeline
Apr 1, 2013 → Jan 1, 2016
NCT ID
NCT01808092About ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator)
ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator) is a phase 3 stage product being developed by Pfizer for Nosocomial Pneumonia (NP). The current trial status is completed. This product is registered under clinical trial identifier NCT01808092. Target conditions include Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01808092 | Phase 3 | Completed |
Competing Products
7 competing products in Nosocomial Pneumonia (NP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin; imipenem/cilastitin | Johnson & Johnson | Phase 3 | 77 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| Ceftolozane/Tazobactam | Merck | Phase 1 | 33 |
| vancomycin monotherapy + daptomycin monotherapy | Novartis | Phase 3 | 77 |
| linezolid | Pfizer | Phase 3 | 76 |
| C Group + E Group | Pfizer | Phase 2/3 | 64 |
| Veronate | Bristol Myers Squibb | Pre-clinical | 22 |